Stroman DW - Search Results

1

In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.

Stroman DW, Dajcs JJ, Cupp GA, Schlech BA. Stroman DW, et al. Surv Ophthalmol. 2005 Nov;50 Suppl 1:S16-31. doi: 10.1016/j.survophthal.2005.06.002. Surv Ophthalmol. 2005. PMID: 16257308 Review.

2

Topical ophthalmic moxifloxacin elicits minimal or no selection of fluoroquinolone resistance among bacteria isolated from the skin, nose, and throat.

Lichtenstein SJ, De Leon L, Heller W, Marshall B, Cupp G, Foster K, McLean C, Levy S, Stroman DW. Lichtenstein SJ, et al. Among authors: stroman dw. J Pediatr Ophthalmol Strabismus. 2012 Mar-Apr;49(2):88-97. doi: 10.3928/01913913-20111101-02. Epub 2011 Nov 8. J Pediatr Ophthalmol Strabismus. 2012. PMID: 22074357

3

Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis.

Tauber S, Cupp G, Garber R, Bartell J, Vohra F, Stroman D. Tauber S, et al. Adv Ther. 2011 Jul;28(7):566-74. doi: 10.1007/s12325-011-0037-x. Epub 2011 Jun 14. Adv Ther. 2011. PMID: 21681652 Clinical Trial.

4

Pseudomonas otitidis sp. nov., isolated from patients with otic infections.

Clark LL, Dajcs JJ, McLean CH, Bartell JG, Stroman DW. Clark LL, et al. Among authors: stroman dw. Int J Syst Evol Microbiol. 2006 Apr;56(Pt 4):709-714. doi: 10.1099/ijs.0.63753-0. Int J Syst Evol Microbiol. 2006. PMID: 16585681

5

Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.

D'Arienzo PA, Wagner RS, Jamison T, Bell B, Dajcs JJ, Stroman DW. D'Arienzo PA, et al. Among authors: stroman dw. Adv Ther. 2010 Jan;27(1):39-47. doi: 10.1007/s12325-010-0004-y. Epub 2010 Feb 19. Adv Ther. 2010. PMID: 20174904

6

A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis.

Kernt K, Martinez MA, Bertin D, Stroman D, Cupp G, Martínez C, Tirado M, Guasch J; International Tobrex2x Group (Eu). Kernt K, et al. Eur J Ophthalmol. 2005 Sep-Oct;15(5):541-9. Eur J Ophthalmol. 2005. PMID: 16167284 Clinical Trial.

7

The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.

Benitez-Del-Castillo J, Verboven Y, Stroman D, Kodjikian L. Benitez-Del-Castillo J, et al. Clin Drug Investig. 2011;31(8):543-557. doi: 10.2165/11589020-000000000-00000. Clin Drug Investig. 2011. PMID: 21604820

8

Effectiveness of mupirocin and polymyxin B in experimental Staphylococcus aureus, Pseudomonas aeruginosa, and Serratia marcescens keratitis.

Moreau JM, Conerly LL, Hume EB, Dajcs JJ, Girgis DO, Cannon BM, Thibodeaux BA, Stroman DW, O'Callaghan RJ. Moreau JM, et al. Among authors: stroman dw. Cornea. 2002 Nov;21(8):807-11. doi: 10.1097/00003226-200211000-00016. Cornea. 2002. PMID: 12410042

9

The effectiveness of tobramycin and Ocuflox in a prophylaxis model of Staphylococcus keratitis.

Dajcs JJ, Moreau JM, Stroman DW, Schlech BA, Ke TL, Thibodeaux BA, Girgis DO, Caballero AR, O'Callaghan RJ. Dajcs JJ, et al. Among authors: stroman dw. Curr Eye Res. 2001 Jul;23(1):60-3. doi: 10.1076/ceyr.23.1.60.5417. Curr Eye Res. 2001. PMID: 11821987

10

A highly virulent Staphylococcus aureus: rabbit anterior chamber infection, characterization, and genetic analysis.

Balzli CL, Bartell J, Dajcs JJ, McCormick CC, Caballero AR, Stroman D, O'Callaghan RJ. Balzli CL, et al. Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5114-20. doi: 10.1167/iovs.10-5179. Epub 2010 May 12. Invest Ophthalmol Vis Sci. 2010. PMID: 20463315

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters